Extended Data Fig. 10: Targeting FSP1 or its genetic deletion reduces intranodal tumour growth and LN metastasis.
From: Lymph node environment drives FSP1 targetability in metastasizing melanoma
a, Schematic of the experimental design for intranodal implantation of SK-MEL5 cells into NSG mice, followed by treatment with FSP1 inhibitors, BSO, or their combinations. The diagram was created using BioRender. b, Schematic of the experimental design for intranodal or subcutaneous implantation of LN7 1134BL WT or FSP1 KO cells into C57BL/6J mice treated with viFSP1. The diagram was created using BioRender. c–h, Representative tumour growth curves from one of the two independent experiments corresponding to Fig. 5g (c–f) and Fig. 5h (g,h). i, Kaplan–Meier survival curves of NSG mice treated intranodally with vehicle (n = 9) or FSEN1 (n = 8). j–q, Representative tumour growth curves from one of the two independent experiments from Fig. 5i showing intranodal (j–m) and subcutaneous (n–q) tumour growth of LN7 1134BL WT and FSP1 KO lines ± viFSP1. r, Quantification of lung metastases (number of nodules) from intravenous injection of LN7 1134BL WT (n = 19) and FSP1 KO cells (n = 21). Data combined 2 independent experiments (Exp1: white dots; Exp2: grey dots). s, Subcutaneous tumour growth curves for LN7 1134BL WT and FSP1 KO cells. Representative curves from 1 of 2 independent experiments. t, Quantification of spontaneous lymph node metastases in draining lymph nodes from 2 independent experiments including subcutaneous LN7 1134BL WT (n = 11) or FSP1 KO tumours (n = 13). u, Representative images of LNs from 1 of 2 independent experiments. Statistical significance was determined using the log-rank (Mantel–Cox) test for survival curve comparisons (i), Mann-Whitney test (r) and contingency analysis using Chi-square with Fisher’s exact test (t).
